Adverse Drug Events to Biomedicines

  • Giuseppe Tridente


Adverse Drug Events (ADEs) are commonly differentiated in two classes: Type A, as predictable reactions related to the pharmacological properties of the drug in study; Type B, as unpredictable events in predisposed individuals. The former group includes side effects, toxicity of overdose, secondary effects, and drug interactions. Overall, they contribute for about 80–90 % of ADEs. The latter group includes hypersensitivity (immunological) reactions, and non-specific reactions, such as pseudo-allergic (anaphylactoid) reactions and idiosyncrasy, all contributing for the remaining 10–20 % of events [1, 2].


Aplastic Anemia Adverse Drug Event Frequency Classification Autoinflammatory Disease Biological Adverse Event 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rawlins M, Thompson W (1991) Mechanisms of adverse drug reactions. In: Davies D (ed) Textbook of adverse drug reactions. Oxford University Press pg, New York, pp 18–45Google Scholar
  2. 2.
    Schnyder B, Pichler WJ (2009) Mechanisms of drug-induced allergy. Mayo Clin Proc 84:268–272PubMedCrossRefGoogle Scholar
  3. 3.
    Aronson JK, Ferner RE (2003) Joining the DoTS: new approach to classify adverse drug reactions. BMJ 327:1222–1225PubMedCrossRefGoogle Scholar
  4. 4.
    Ferner RE, Butt TF (2012) Adverse drug reactions. Med 40:366–370Google Scholar
  5. 5.
    French LE Adverse Cutaneous drug eruptions. In : Ring J et al (eds) Chemical Immunology and Allergy, Karger, 97:1–240Google Scholar
  6. 6.
    Napoleone E (2011) Children and ADRs (Adverse Drug Reactions). Ital J Pediat 36:e1–e5Google Scholar
  7. 7.
    Horen B, Montastruc J-L and Lapeyre-Mestre (2002) Adverse drug reactions and off-label drug use in pediatric outpatients. Br J Clin Pharmacol 54:665–670Google Scholar
  8. 8.
    Giezen TJ, Mantel-Teeuwisse AK, Straus SMJM et al (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300:1887–1896PubMedCrossRefGoogle Scholar
  9. 9.
    Gerber BO, Pichler WJ (2006) Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions. AAPS J 8:e160–e165PubMedCrossRefGoogle Scholar
  10. 10.
    Lee SJ, Kavanaugh A (2005) Adverse reactions to biologic agents: focus on autoimmune therapies. J Allergy Clin Immunol 116:900–905PubMedCrossRefGoogle Scholar
  11. 11.
    Sherer K, Spoerl D, Bircher AJ (2010) Adverse drug reactions to biologics. JDDG 8:411–426Google Scholar
  12. 12.
    Clarke JB (2010) Mechanisms of adverse drug reactions to biologics. In : Uetrecht J (ed) Adverse Drug Reactions. Handbook of Experimental Pharmacology. Springer, New York 196:453–474Google Scholar

Copyright information

© Springer-Verlag Italia 2014

Authors and Affiliations

  1. 1.University of VeronaVeronaItaly

Personalised recommendations